Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's ...

Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...

BERKELEY, Calif. and MAINZ, Germany - Mainz Biomed NV (NASDAQ:MYNZ), a company focused on early cancer detection diagnostics, has announced its return to compliance with Nasdaq's stockholders' equity ...

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements ...

Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

AArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average ...

AArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients ...

1 Day MYNZ 13.28% DJIA 0.52% Russell 2K 1.13% Health Care/Life Sciences 0.39% ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle mass.